These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 32159712

  • 1. Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study.
    De Berardis D, Fornaro M, Anastasia A, Vellante F, Olivieri L, Rapini G, Serroni N, Orsolini L, Valchera A, Carano A, Tomasetti C, Ventriglio A, Bustini M, Pompili M, Serafini G, Perna G, Iasevoli F, Martinotti G, Di Giannantonio M.
    Braz J Psychiatry; 2020; 42(3):317-321. PubMed ID: 32159712
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
    Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I.
    Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
    [Abstract] [Full Text] [Related]

  • 4. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
    Nierenberg AA, Loft H, Olsen CK.
    J Affect Disord; 2019 May 01; 250():35-42. PubMed ID: 30826492
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of vortioxetine on the physical symptoms of major depressive disorder.
    Christensen MC, Florea I, Lindsten A, Baldwin DS.
    J Psychopharmacol; 2018 Oct 01; 32(10):1086-1097. PubMed ID: 30047820
    [Abstract] [Full Text] [Related]

  • 6. Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to SSRI Therapy: Results of the VIVRE Study.
    McIntyre RS, Florea I, Pedersen MM, Christensen MC.
    J Clin Psychiatry; 2023 May 22; 84(4):. PubMed ID: 37227402
    [Abstract] [Full Text] [Related]

  • 7. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR, Jacobsen PL, Chen Y.
    Curr Med Res Opin; 2013 Mar 22; 29(3):217-26. PubMed ID: 23252878
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response.
    Papakostas GI, Nielsen RZ, Dragheim M, Tonnoir B.
    J Psychiatr Res; 2018 Jun 22; 101():72-79. PubMed ID: 29554497
    [Abstract] [Full Text] [Related]

  • 9. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder.
    Iosifescu DV, Nierenberg AA, Mischoulon D, Perlis RH, Papakostas GI, Ryan JL, Alpert JE, Fava M.
    J Clin Psychiatry; 2005 Aug 22; 66(8):1038-42. PubMed ID: 16086620
    [Abstract] [Full Text] [Related]

  • 10. S-Adenosyl-L-Methionine augmentation in patients with stage II treatment-resistant major depressive disorder: an open label, fixed dose, single-blind study.
    De Berardis D, Marini S, Serroni N, Rapini G, Iasevoli F, Valchera A, Signorelli M, Aguglia E, Perna G, Salone A, Di Iorio G, Martinotti G, Di Giannantonio M.
    ScientificWorldJournal; 2013 Aug 22; 2013():204649. PubMed ID: 23766680
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study.
    Di Nicola M, Adair M, Rieckmann A, Christensen M C.
    J Psychopharmacol; 2024 Jul 22; 38(7):615-623. PubMed ID: 39077889
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.
    Fagiolini A, Florea I, Loft H, Christensen MC.
    J Affect Disord; 2021 Mar 15; 283():472-479. PubMed ID: 33516560
    [Abstract] [Full Text] [Related]

  • 13. Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study.
    Adair M, Bose R, Schmidt SN.
    Curr Med Res Opin; 2024 Sep 15; 40(9):1637-1645. PubMed ID: 39110846
    [Abstract] [Full Text] [Related]

  • 14. The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis.
    Zheng J, Wang Z, Li E.
    Afr Health Sci; 2019 Mar 15; 19(1):1716-1726. PubMed ID: 31149002
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study.
    Wang J, Liu XF, Feng C, Bao Q, Fu HR.
    Int J Psychiatry Clin Pract; 2019 Nov 15; 23(4):245-250. PubMed ID: 29113521
    [Abstract] [Full Text] [Related]

  • 16. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME.
    Int J Neuropsychopharmacol; 2013 Mar 15; 16(2):313-21. PubMed ID: 22963932
    [Abstract] [Full Text] [Related]

  • 17. Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder.
    Umbricht D, Niggli M, Sanwald-Ducray P, Deptula D, Moore R, Grünbauer W, Boak L, Fontoura P.
    J Clin Psychiatry; 2020 Jul 14; 81(4):. PubMed ID: 32663909
    [Abstract] [Full Text] [Related]

  • 18. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G, Wang X, Ma D.
    Clin Drug Investig; 2016 Jul 14; 36(7):509-17. PubMed ID: 27067232
    [Abstract] [Full Text] [Related]

  • 19. Novel Augmentation Strategies in Major Depression.
    Martiny K.
    Dan Med J; 2017 Apr 14; 64(4):. PubMed ID: 28385173
    [Abstract] [Full Text] [Related]

  • 20. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
    Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A.
    CNS Spectr; 2019 Dec 14; 24(6):616-627. PubMed ID: 30802419
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.